Neoadjuvant therapy (NAT) has become routine in patients with borderline resectable pancreatic cancer. Pathologists examine pancreatic cancer resection specimens to evaluate the effect of NAT. However, an automated scoring system to objectively quantify residual pancreatic cancer (RPC) is currently lacking. Herein, we developed and validated the first automated segmentation model using artificial intelligence techniques to objectively quantify RPC. Digitized histopathological tissue slides were included from resected pancreatic cancer specimens from 14 centers in 7 countries in Europe, North America, Australia, and Asia. Four different scanner types were used: Philips (56%), Hamamatsu (27%), 3DHistech (10%), and Leica (7%). Regions of interest were annotated and classified as cancer, non-neoplastic pancreatic ducts, and others. A U-Net model was trained to detect RPC. Validation consisted of by-scanner internal-external cross-validation. Overall, 528 unique hematoxylin and eosin (H & E) slides from 528 patients were included. In the individual Philips, Hamamatsu, 3DHistech, and Leica scanner cross-validations, mean F1 scores of 0.81 (95% CI, 0.77-0.84), 0.80 (0.78-0.83), 0.76 (0.65-0.78), and 0.71 (0.65-0.78) were achieved, respectively. In the meta-analysis of the cross-validations, the mean F1 score was 0.78 (0.71-0.84). A final model was trained on the entire data set. This ISGPP model is the first segmentation model using artificial intelligence techniques to objectively quantify RPC following NAT. The internally-externally cross-validated model in this study demonstrated robust performance in detecting RPC in specimens. The ISGPP model, now made publically available, enables automated RPC segmentation and forms the basis for objective NAT response evaluation in pancreatic cancer.

中文翻译：

---

基于人工智能的新辅助治疗后切除标本中残留胰腺癌的分割 (ISGPP-2)：国际改进和验证研究。


新辅助治疗（NAT）已成为边缘性可切除胰腺癌患者的常规治疗。病理学家检查胰腺癌切除标本以评估 NAT 的效果。然而，目前缺乏客观量化残余胰腺癌（RPC）的自动评分系统。在此，我们开发并验证了第一个使用人工智能技术客观量化 RPC 的自动分割模型。数字化组织病理学组织切片来自欧洲、北美、澳大利亚和亚洲 7 个国家 14 个中心的切除胰腺癌标本。使用四种不同的扫描仪类型：飞利浦 (56%)、滨松 (27%)、3DHistech (10%) 和徕卡 (7%)。感兴趣的区域被注释并分类为癌症、非肿瘤性胰管等。 U-Net 模型经过训练来检测 RPC。验证包括扫描仪内部外部交叉验证。总体而言，包括来自 528 名患者的 528 张独特的苏木精和伊红 (H & E) 玻片。在飞利浦、滨松、3DHistech 和 Leica 扫描仪的单独交叉验证中，平均 F1 分数为 0.81（95% CI，0.77-0.84）、0.80（0.78-0.83）、0.76（0.65-0.78）和 0.71（0.65-0.71）。 0.78）分别达到。在交叉验证的荟萃分析中，平均 F1 得分为 0.78 (0.71-0.84)。最终模型是在整个数据集上进行训练的。该ISGPP模型是第一个使用人工智能技术来客观量化NAT之后的RPC的分段模型。本研究中的内部-外部交叉验证模型在检测样本中的 RPC 方面表现出强大的性能。 ISGPP 模型现已公开，可实现自动 RPC 分割，并构成胰腺癌客观 NAT 反应评估的基础。